Perigon Wealth Management LLC Purchases New Stake in 4D Molecular Therapeutics, Inc. $FDMT

Perigon Wealth Management LLC acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 146,185 shares of the company’s stock, valued at approximately $1,944,000.

Several other large investors also recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in 4D Molecular Therapeutics during the 2nd quarter worth $354,000. Persistent Asset Partners Ltd acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $1,936,000. Bank of New York Mellon Corp purchased a new position in 4D Molecular Therapeutics in the second quarter valued at about $2,026,000. Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock worth $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. The trade was a 53.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Kirn sold 114,746 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares in the company, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 200,496 shares of company stock valued at $2,240,244. 7.90% of the stock is owned by company insiders.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $14.55 on Tuesday. The stock has a market cap of $760.67 million, a P/E ratio of -5.53 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $11.06 and a 200-day moving average of $9.93. 4D Molecular Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $15.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, analysts expect that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.